Kornimate/medical-research-clean huggingface dataset:
cardiac function in severe aneurysmal subarachnoid haemorrhage patients

Conditions: Aneurysmal Subarachnoid Haemorrhage; World Neurosurgeon Federation Score ≥ III

Summary: cardiac dysfunction can occur in aneurysmal subarachnoid haemorrhage and might impact patient's neurologic outcome condition aneurysmal subarachnoid haemorrhage world neurosurgeon federation score ≥ iii

trans-thoracic echocardiography on day 1, day 3 and day 7 speckle-tracking of echocardiographic loops by a cardiologist blinded to the patient's management and outcome

Eligibility criteria:
inclusion criteria: * aneurysmal subarachnoid haemorrhage * world neurosurgeon federation score ≥ iii * written information to next-of-kin and patients when possible exclusion criteria: * history of myocardial infarction, chronic heart failure with nyha ≥ 2, major heart surgery * lack of acoustic window to perform trans-thoracic echocardiography

Keywords: aneurysmal subarachnoid haemorrhage
the effect of pressure controlled ventilation on the pulmonary mechanics in prone position using the wilson frame: a comparison with volume controlled ventilation

Conditions: Herniation of Lumbar Vertebral Disc

Summary: prone position in spinal surgery can increase airway pressure and decrease dynamic lung compliance by a frame used for postural stabilization. also, it can increase hemodynamic instability such as reduced blood pressure by aggravating cardiac index. former study shows pressure controlled ventilation on the pulmonary mechanics can improve alveolar use and oxygenation than volume controlled ventilation. the latter one means controlling a patient's breathing completely through tidal volume and set breathing rate. this could be useful for the patients not possible to breath by themselves because it guarantees the perfect breathing. the pressure controlled ventilation is used when there is a possibility to change a patient's environment. the pressure will be maintained steadily, but volume and flux will be changed. that means through the pressure already set, the whole breathing will be maintained from the beginning to end. if a patient's resistance is increased, the volume will be decreased even though the way of blood pressure control is same. however, the tidal volume per minute can be controlled somewhat and barotrauma can be decreased by controlling respiratory rate. through this study, we are expecting the pressure controlled ventilation in prone position can improve lung mechanics and oxygenation.


Eligibility criteria:
inclusion criteria: * scheduled for lumbar spine surgery under general anaesthesia exclusion criteria: * patients with coronary artery occlusive disease * morbid obesity (body mass index ≥ 30 kg/m2) * cerebrovascular disease and major obstructive or restrictive pulmonary disease
kvus at neoadjuvant ctx of breast cancer

Conditions: Early Primary Breast Cancer

Summary: effect of the contrast-enhanced diagnostic ultrasound during neoadjuvant chemotherapy of breast cancer on the achieved tumor size reduction and tolerability of chemotherapy

the 5-year survival rate of breast cancer patients is decreasing in the advanced, metastatic stage from 99% to 26%. therefore an optimization of the therapy of advanced breast cancer is urgently needed. to increase the echogenicity of the blood in the ultrasound, microbubbles were developed working as stable, biocompatible contrast agent in ultrasound. such a clinically approved ultrasound contrast agent is sonovue® (bracco international b.v., amsterdam). sonovue® is approved by the european medicines agency (ema) (approval number eu/1/01/177/002) for the visualization of focal vascularization lesions of the liver and breast within doppler sonography and is applied in breast cancer patients primarily for the purpose of diagnosis as well as to evaluate the response to the neoadjuvant used chemotherapy. animal studies using the contrast enhanced ultrasound have shown that the administration of this contrast agent increases the penetration and accumulation of drugs in the tumor as well as the permeability of the blood-brain barrier resulting in a precise and effective drug distribution. in the tumor animal model it could be shown that a combined treatment with chemotherapy and contrast enhanced ultrasound results in a decreased tumor growth and a prolonged survival. patients with inoperable pancreatic cancer showed a reduced tumor growth and better tolerability of chemotherapy when administrating the contrast enhanced diagnostic ultrasound during palliative chemotherapy. this could be due to the better tumor response, but also due to the more targeted chemotherapy distribution. the purpose of this study is to examine whether the use of the contrast enhanced diagnostic ultrasound during neoadjuvant chemotherapy results in an increased tumor regression in comparison to native ultrasound. it is an investigator initiated trial and is funded by internal means.

Eligibility criteria:
inclusion criteria: * written informed consent * age \> 18 yrs * histologically confirmed primary breast cancer including all intrinsic subtypes * treatment with neoadjuvant chemotherapy * persons who are legally competent and mentally able to follow the instructions of the study team exclusion criteria: * hypersensitivity / allergy to sulfur hexafluoride, macrogol 4000, distearoylphosphatidylcholine, dipalmitoylphosphatidylglycerol-sodium, palmitic acid * right-left shunt, * severe pulmonary hypertension (pulmonary arterial pressure \> 90 mmhg) * uncontrolled systemic hypertension * acute respiratory distress syndrome * pregnancy * commitment of the patient to any resident institution by order of any court or authority * expectation of missing compliance * alcohol or drug abuse * patients who are in a relationship of dependence or in a working relationship to the sponsor, the investigator or his representative

Keywords: breast cancer, neoadjuvant chemotherapy, ultrasound, microbubbles
importance of sleep deprivation in differential diagnosis of primary hypersomnia (actisom dépistage)

Conditions: Hypersomnia

Summary: 7 to 14 days actimetry recording in order to exclude sleep deprivation just before hospitalisation for differential diagnosis of hypersomnia

this is an observational study urine drug screening will also be performe the suty includes four centers in france the study duration is of one year

Eligibility criteria:
inclusion criteria: * men or women aged \> 18 years * patient with a sleepiness evoking a primary hypersomnia * epworth sleepiness scale \> 10 * information note signed exclusion criteria: * patient with type 1 or 2 narcolepsy and/or known hypersomnia * frank cataplexy * not stable metabolic, neurological or psychiatric disease * patient treated by a medicine acting on the central nervous system * patient having a shift work or having made a transmeridian flight of more than 3 hours lag in the previous month the research * non affiliation to social security * pregnancy * patient under guardianship or curatorship

Keywords: actimetry
superselective adrenal arterial embolization for resistant hypertension

Conditions: Resistant Hypertension

Summary: resistant hypertension (rh) is usually defined as blood pressure (bp) that remains above guideline-specified targets despite the use of three or more antihypertensive agents at optimal or maximally tolerated doses, with one of those agents preferably being a diuretic. it is not uncommon, being identified in 10 to 30% of hypertensive patients and it is known to be a risk factor for cardiovascular (cv) events, including stroke, myocardial infarction (mi), heart failure (hf), and cv mortality, as well as adverse renal events,including chronic kidney disease (ckd) and end-stage kidney disease (eskd). the activation of the renin-angiotensin-aldosterone system (raas) and sympatho-adrenomedullary system can play a pathogenic role in triggering and sustaining rh. saae is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines. therefore, saae is a minimally invasive procedure that might be used as an alternative strategy to antihypertensive drugs or reduce the intensity of antihypertensive drugs.

not provided

Eligibility criteria:
inclusion criteria: * male or female, aged between 18-65 years old. * patients with resist hypertension (office systolic blood pressure ≥140 mmhg, and/or office diastolic blood pressure ≥90 mmhg, and/or 24-h average systolic blood pressure ≥130 mmhg) with rational lifestyle change and triple antihypertensive drugs (irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d) for at least 4 weeks. * informed consent signed and agreed to participate in this trial. exclusion criteria: * secondary hypertension * adrenergic insufficiency. * adrenocortical insufficiency * renal failure egfr\<60 ml/min/1.73 m2 * heart failure with nyha grade ⅱ-ⅳ grade or unstable angina, severe cardiovascular and cerebrovascular stenosis, myocardial infarction, intracranial aneurysm, stroke and other acute cardiovascular events. * acute infections, tumors and severe arrhythmias, psychiatric disorders, drugs or alcohol addicts. * liver dysfunction or the following history of liver disease: ast or alt 3 times higher than the upper limit, liver cirrhosis, history of hepatic encephalopathy, esophageal variceal history or portal shunt history. * fertile woman without contraceptives. * coagulation dysfunction. * pregnant women or lactating women. * participated in other clinical trials or admitted with other research drugs within 3 months prior to the trial. * any surgical or medical condition which can significantly alter the absorption, distribution, metabolism, or excretion of any study drug. * allergy or any contraindications for the study drugs, contrast agents and alcohol. * history of depression, schizophrenia or vascular dementia. * refused to sign informed consent
efficacy and safety of short course therapy with peginterferon alpha-2b (peg-ifn alfa-2b) and ribavirin (rbv) for chronic hepatitis c (genotype 4) participants achieving a rapid virological response at week 4 of treatment (mk-8908b-059)

Conditions: Hepatitis C, Chronic

Summary: the purpose of this study is to assess the efficacy of a short course of therapy (24 weeks) versus standard 48 week treatment in previously untreated adult participants with chronic hepatitis c (chc) genotype 4 infection who achieve rapid virologic response (rvr), defined as hcv ribonucleic acid (rna) negativity after 4 weeks of treatment.

participants who achieved rvr after 4 weeks of peg-inf alfa-2b plus rbv treatment were randomized to receive either 20 or 44 weeks of continued therapy, for a total of 24 or 48 weeks total of peg-inf plus rbv therapy.

Eligibility criteria:
inclusion criteria: * participant is ≥40 kg and ≤120 kg weight * participant and participant's partner(s) must each agree to use acceptable methods of contraception for at least 2 weeks prior to day 1 and continue until at least 6 months after last dose of study medication, or longer if dictated by local regulations. * previously documented chc genotype 4 infection * liver biopsy or fibrotest and fibroscan with histology consistent with chc and no other etiology and with hepatic fibrosis scores (f0, f1, f2, f3). exclusion criteria: * co-infected with the human immunodeficiency virus (hiv) or hepatitis b virus * treatment for hepatitis c with any investigational medication * treatment with any investigational drug within 30 days of the screening visit * evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy * autoimmune hepatitis or a history of autoimmune disease * hepatic fibrosis score f4 * severe pre-existing cardiac disease, including unstable or uncontrolled cardiac disease in the previous six months * autoimmune hepatitis or a history of autoimmune disease * thyroid disease uncontrolled with conventional treatment * epilepsy and/or compromised central nervous system (cns) function
acupuncture for chronic constipation

Conditions: Chronic Constipation

Summary: since there have been few advances for constipation in laxative treatment in the last 50 years, this study is designed to evaluate the efficacy and safety of acupuncture for patients with chronic constipation based on the theory of traditional chinese medicine.

although many people regard regular defecation as important factor to maintain healthy, constipation is still a common problem in general population. because the symptoms cause serious impairment of life quality, laxatives are commonly prescribed for people and over prescribing of laxatives is also common. despite the large sums spent on laxatives, there have been few advances in laxative treatment in the last 50 years and there have been minimal research addressing the problem. since there is unsatisfactory effect by current pharmacologic therapies and preventive strategies, we look forward to the practice of traditional chinese medicine, which had abundant clinical experiences and medical records in the past of thousands years ago. therefore we aim to do the research to create the evidence of acupuncture on the safety, efficacy and quality of life for chronic constipation.

Eligibility criteria:
inclusion criteria: * men or non-pregnant women who are at least 20 years old * who meet any one of the following three criteria: 1.the one who meets romeiii criteria; 2.at least once a week of enema/suppository in past three months; 3.laxative use in more than half time of last three months exclusion criteria: * known colorectal cancer, anal abscess, anal fissure, rectocele, inflammatory bowel disease, megacolon or mechanical bowel obstruction * unknown cause of gastrointestinal bleeding or acute infection * history of alcohol or drug abuser * women who are pregnant, as determined by a urine pregnancy test * history of adverse reaction to (electro)acupuncture * received herb or acupuncture therapy within one month prior to enrollment

Keywords: chronic constipation electroacupuncture randomized controlled trial
panda gym: automated assessment of neurodevelopment in infants at risk for motor disability

Conditions: Pediatric ALL; Infant Development; Neurodevelopmental Disorders

Summary: early childhood detection of motor delays or impairments provides the opportunity for early treatment which improves health outcomes. this study will use state of the art sensors combined with machine learning algorithms to develop objective, accurate, easy-to-use tools for the early scoring of deficits and lays the foundation for the early prediction of physical disability.

for children with neurodevelopmental disabilities, early treatment in the first year of life improves long-term outcomes. however, the investigators are currently held back by inadequacies of available clinical tests to measure and predict impairment. existing tests are hard to administer, require specialized training, and have limited long-term predictive value. there is a critical need to develop an objective, accurate, easy-to-use tool for the early prediction of long-term physical disability. the field of pediatrics and infant development would greatly benefit from a quantitative score that would correlate with existing clinical measures used today to detect movement impairments in very young infants. to realize a new generation of tests that will be easy to administer, the investigators will obtain large datasets of infants playing in an instrumented gym or simply being recorded while moving in a supine posture. video and sensor data analyses will convert movement into feature vectors based on our knowledge of the problem domain. our approach will use machine learning to relate these feature vectors to currently recommended clinical tests or other ground truth information. the power of this design is that algorithms can utilize many aspects of movement to produce the relevant scores.

Eligibility criteria:
infants, male and female, between 0-6 months (infants older than 6 months before initial enrollment will be excluded). * infants with early brain injury (ebi): * hydrocephalus * hypoxic-ischemic encephalopathy (hie) * periventricular leukomalacia (pvl) * intraventricular hemorrhage (ivh) * stroke * healthy infants (controls): o no history of early brain injury (ebi) * infants without ebi/risk for future disability: * infants without known brain injuries, but with a history of preterm birth less than 32-week gestation with significant medical problems, difficulty eating, or who lack head control at 4 months of age or later will be classified as moderate risk.

Keywords: infants neurodevelopment developmental delays electronics early intervention sensory and motor nicu natural play
effectiveness of early parental sensitivity intervention for preterm infant mothers

Conditions: Attachment; Parental Stress

Summary: in taiwan, according to the birth notification statistics of the ministry of health and welfare. 164,496 newborns were born in 2020, with preterm births accounting for about 11.58%.most preterm infants need to be hospitalized for highly specialized care, resulting in the separation of preterm infants from their parents after birth, which may have a negative impact on the healthy attachment development between parents and preterm infants. moreover, due to the vulnerability of preterm infants, parents often lack the confidence to take care of them.

the study was a quantitative study of a randomized controlled trial, designed by experimental research method. using gpower 3.1.2 to estimate the number of samples, and the statistical method chosen was repeated measures anova, the sample size was 80. the subjects were divided into two groups, the control group received general routine nursing guidance, while the experimental group received general routine nursing guidance and early parental sensitivity intervention program. using the nicu vr tour and premature infant behavioral clues teaching materials as educational tools for early parental sensitivity intervention program. the outcome used the maternal attachment inventory, maternal confidence questionnaire and parental stressor scale: infant hospitalization as evaluated tools.

Eligibility criteria:
inclusion criteria: 1. preterm infants: 1. preterm infants less than 37 weeks gestation and hospitalized in the nicu 2. the birth weight is classified as vlbw and lbw, and the birth weight is between 1,000-2,499gm 2. preterm infant mothers: 1. children have not been hospitalized in the nicu in the past 2. at least 20 years old 3. they can speak chinese, taiwanese fluently and need to be literate exclusion criteria: 1. preterm infants : 1. combined congenital diseases and chromosomal abnormalities 2. immediate surgery, first aid and unstable vital signs are necessary after birth 3. the birth weight is classified as elbw, and the birth weight is less than 1,000gm 2. preterm infant mothers: 1. hospitalized in the intensive care unit

Keywords: preterm infant mothers early parental sensitivity intervention attachment parenting confidence parental stress
short-term clinical follow-up of the vascular closure device mantatm in minimally invasive cardiac surgery

Conditions: Femoral Artery Injury; Aortic Valve Insufficiency

Summary: the percutaneous manta vascular closure device is dedicated to the closure of large bore arteriotomies. it appears to be a safe and doable option for vascular access closure in patients undergoing transfemoral transcatheter aortic valve implantation. data concerning safety and efficacy of manta vascular closure device in minimally invasive cardiac surgery are scarce. this study aim to assess this novel collagen-based technology in minimal invasive aortic valve replacement surgery.


Eligibility criteria:
inclusion criteria: * subject voluntarily agreeing to participate in the study * subject \>= 18 years of age * patients operated between december 16, 2019 and june 30, 2021 from minimally invasive cardiac surgery with femoral cannulation for cardiopulmonary bypass in dijon university hospital * patients in whom the manta device has been used for femoral artery closure exclusion criteria: not applicable
understanding how methadone treatment during surgery affects pain levels and the need for pain medications after surgery

Conditions: Spinal Surgery

Summary: the researchers are doing this study to find out whether giving methadone during spinal surgery helps manage pain in the first 72 hours after surgery better than other standard pain medications. participants' pain will be measured by how much pain is reported after surgery, and how much additional pain medication is needed to lower pain levels. the researchers will look at whether giving methadone during surgery reduces the need for other pain medications after surgery. in addition, the team will compare the effects of the two standard treatments- one with methadone and one without methadone to to evaluate which one works best.


Eligibility criteria:
inclusion criteria: * adult patients (between 18-75 years of age) scheduled for extradural spine surgery with instrumentation (greater than or equal to two levels and including minimally invasive) of expected duration ≥ 2 hours * postoperative hospital stay expected to be ≥ 2 nights at the time of consent exclusion criteria: * use of methadone currently or within the previous 6 weeks * drug misuse history (e.g., ketamine, cocaine, heroin, amphetamine, methamphetamine, mdma, phencyclidine, lysergic acid, mescaline, psilocybin). * current use of opioid antagonist/partial antagonist (i.e. buprenorphine). * current or past diagnosis of a major psychiatric disorder (such as schizophrenia, dementia, delirium). * patients with a bmi ≥ 36 kg/m2 * 2nd or 3rd degree heart block as assessed by preoperative ekg. * qtc \> 450 msec on preoperative ekg. * documentation of congestive heart failure and/or ejection fraction \< 30% if recorded in the pre-operative record. * contraindication to use of any analgesic medications listed in the eras pathways (acetaminophen, gabapentin, celecoxib, iv opioids). * any known hypersensitivity to methadone. * pregnant or breastfeeding. * abnormal liver function tests as related to the msk guidelines for use of iv acetaminophen: alt greater than 2 x upper limit of normal (\> 75 u/l) * serum creatinine \> 1.5 mg/dl * instrumented spine cases of less than 2 levels * all non-instrumented spine cases * all intradural tumor resections * all "take backs" that occur within 72 hours of surgery (wound revisions, hematomas, etc.)

Keywords: methadone pain levels pain medications 22-015